← All trials
NCT05665530
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Dec 26, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 51
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Prelude TherapeuticsLead sponsor
Drugs studied
Indications studied
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Leukemia, B-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Lymphoma, T-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.